2022 意大利专家意见：达雷妥尤单抗治疗多发性骨髓瘤感染风险的管理

2023-04-30 国外血液科相关专家小组 Crit Rev Oncol Hematol 发表于上海

达雷妥尤单抗被批准用于心真大或复发/难治性多发性骨髓瘤（MM）,该药物的使用改善了患者的预后，但也改变可感染的频率。本文主要针对接受或正在接受达雷妥尤单抗治疗的MM候选患者提供最佳感染控制建议。

中文标题：

英文标题：

Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel

发布机构：

国外血液科相关专家小组

发布日期：

2023-04-30

简要介绍：

达雷妥尤单抗被批准用于心真大或复发/难治性多发性骨髓瘤（MM）,该药物的使用改善了患者的预后，但也改变可感染的频率。本文主要针对接受或正在接受达雷妥尤单抗治疗的MM候选患者提供最佳感染控制建议。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=9fc0a1c003a1396f, title=2022 意大利专家意见：达雷妥尤单抗治疗多发性骨髓瘤感染风险的管理, enTitle=Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel, guiderFrom=Crit Rev Oncol Hematol, authorId=0, author=, summary=达雷妥尤单抗被批准用于心真大或复发/难治性多发性骨髓瘤（MM）,该药物的使用改善了患者的预后，但也改变可感染的频率。本文主要针对接受或正在接受达雷妥尤单抗治疗的MM候选患者提供最佳感染控制建议。, cover=https://img.medsci.cn/20221109/1668016274166_4754896.png, journalId=0, articlesId=null, associationId=971, associationName=国外血液科相关专家小组, associationIntro=null, copyright=0, guiderPublishedTime=Sun Apr 30 00:00:00 CST 2023, originalUrl=, linkOutUrl=, content=<div class="guideDetailsCont flex-row-between-start" style="color: #333333;"> <div class="detailsContRight" style="color: #222222;">达雷妥尤单抗被批准用于心真大或复发/难治性多发性骨髓瘤（MM）,该药物的使用改善了患者的预后，但也改变可感染的频率。本文主要针对接受或正在接受达雷妥尤单抗治疗的MM候选患者提供最佳感染控制建议。</div> </div> <div class="detailsQRWrapper" style="color: #333333;"> <div id="app_detail" class="detailsQR" title="https://m.medlive.cn/guide/1/30127"> </div> </div>, tagList=[TagDto(tagId=321, tagName=多发性骨髓瘤), TagDto(tagId=91930, tagName=达雷妥尤单抗)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=321, articleKeyword=多发性骨髓瘤, articleKeywordNum=6, guiderKeywordId=321, guiderKeyword=多发性骨髓瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=661, appHits=32, showAppHits=0, pcHits=53, showPcHits=629, likes=0, shares=8, comments=8, approvalStatus=1, publishedTime=Wed Oct 25 21:35:00 CST 2023, publishedTimeString=2023-04-30, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Wed Oct 25 15:37:36 CST 2023, updatedBy=8538692, updatedName=梅斯话题小助手, updatedTime=Sat Jan 06 02:33:14 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=上海, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 意大利专家意见：达雷妥尤单抗治疗多发性骨髓瘤感染风险的管理.pdf)])

2022 意大利专家意见：达雷妥尤单抗治疗多发性骨髓瘤感染风险的管理.pdf

下载请点击：

评论区 (3)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=2165044, encodeId=0b3f2165044b0, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231025/5ba7746d4940429eacf66f47a67b212c/f825219347a84eae98167f286add17e1.jpg, createdBy=59aa9032145, createdName=润去学习了, createdTime=Thu Oct 26 15:19:15 CST 2023, time=2023-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165043, encodeId=74d82165043c4, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231025/5ba7746d4940429eacf66f47a67b212c/f825219347a84eae98167f286add17e1.jpg, createdBy=59aa9032145, createdName=润去学习了, createdTime=Thu Oct 26 15:19:12 CST 2023, time=2023-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165042, encodeId=4b9921650427c, content=很有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231025/5ba7746d4940429eacf66f47a67b212c/f825219347a84eae98167f286add17e1.jpg, createdBy=59aa9032145, createdName=润去学习了, createdTime=Thu Oct 26 15:19:09 CST 2023, time=2023-10-26, status=1, ipAttribution=)]
2023-10-26 润去学习了

不错

16 0
[GetPortalCommentsPageByObjectIdResponse(id=2165044, encodeId=0b3f2165044b0, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231025/5ba7746d4940429eacf66f47a67b212c/f825219347a84eae98167f286add17e1.jpg, createdBy=59aa9032145, createdName=润去学习了, createdTime=Thu Oct 26 15:19:15 CST 2023, time=2023-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165043, encodeId=74d82165043c4, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231025/5ba7746d4940429eacf66f47a67b212c/f825219347a84eae98167f286add17e1.jpg, createdBy=59aa9032145, createdName=润去学习了, createdTime=Thu Oct 26 15:19:12 CST 2023, time=2023-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165042, encodeId=4b9921650427c, content=很有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231025/5ba7746d4940429eacf66f47a67b212c/f825219347a84eae98167f286add17e1.jpg, createdBy=59aa9032145, createdName=润去学习了, createdTime=Thu Oct 26 15:19:09 CST 2023, time=2023-10-26, status=1, ipAttribution=)]
2023-10-26 润去学习了

很好

17 0
[GetPortalCommentsPageByObjectIdResponse(id=2165044, encodeId=0b3f2165044b0, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231025/5ba7746d4940429eacf66f47a67b212c/f825219347a84eae98167f286add17e1.jpg, createdBy=59aa9032145, createdName=润去学习了, createdTime=Thu Oct 26 15:19:15 CST 2023, time=2023-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165043, encodeId=74d82165043c4, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231025/5ba7746d4940429eacf66f47a67b212c/f825219347a84eae98167f286add17e1.jpg, createdBy=59aa9032145, createdName=润去学习了, createdTime=Thu Oct 26 15:19:12 CST 2023, time=2023-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165042, encodeId=4b9921650427c, content=很有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231025/5ba7746d4940429eacf66f47a67b212c/f825219347a84eae98167f286add17e1.jpg, createdBy=59aa9032145, createdName=润去学习了, createdTime=Thu Oct 26 15:19:09 CST 2023, time=2023-10-26, status=1, ipAttribution=)]
2023-10-26 润去学习了

很有用

23 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤指南

2022 意大利专家意见：达雷妥尤单抗治疗多发性骨髓瘤感染风险的管理

相关指南

拓展阅读

科室

工具

服务